Immunovant, Inc. (IMVT)
NASDAQ: IMVT · IEX Real-Time Price · USD
32.52
+1.09 (3.47%)
At close: Mar 27, 2024, 4:00 PM
32.94
+0.42 (1.29%)
After-hours: Mar 27, 2024, 7:47 PM EDT

Immunovant Income Statement

Millions USD. Fiscal year is Apr - Mar.
Year 20222021202020192018
Selling, General & Admin
48.0254.2339.5118.152.69
Research & Development
160.26101.8168.647.9325.73
Other Operating Expenses
100000
Operating Expenses
218.28156.03108.1266.0828.43
Operating Income
-218.28-156.03-108.12-66.08-28.43
Interest Expense / Income
0000.630
Other Expense / Income
-7.330.78-0.33-0.410.16
Pretax Income
-210.95-156.81-107.79-66.29-28.58
Income Tax
0.01-0.08-0.360.10.02
Net Income
-210.96-156.73-107.43-66.39-28.6
Shares Outstanding (Basic)
123110884322
Shares Outstanding (Diluted)
123110884322
Shares Change
12.21%24.98%103.14%94.85%-
EPS (Basic)
-1.71-1.43-1.22-1.54-1.29
EPS (Diluted)
-1.71-1.43-1.22-1.54-1.29
Free Cash Flow
-188.39-106.37-83.54-53.39-28.6
Free Cash Flow Per Share
-1.53-0.97-0.95-1.24-1.29
EBITDA
-209.63-155.58-106.79-65.65-28.57
Depreciation & Amortization
1.321.2310.020.01
EBIT
-210.95-156.81-107.79-65.67-28.58
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).